Subacute and Chronic Eczematous Dermatitis VolunteersEfficacy and sNCT07867249
Efficacy and Safety of Cream Containing Fig Extract in Subacute and Chronic Eczematous Dermatitis Volunteers
A study testing Fig extract cream in people with Subacute and Chronic Eczematous Dermatitis Volunteers, run by Chulalongkorn University.
Trial summary
This study aims to evaluate the efficacy and safety of a cream containing fig extract in volunteers with subacute and chronic eczematous dermatitis. The affected area of subacute and chronic eczematous dermatitis in each participant will be equally divided into two sections (left and right) using block randomization. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Subacute and Chronic Eczematous Dermatitis Volunteers
- What is being tested?
- Fig extract cream
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 31 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female participants aged 18 years or older.
- Have subacute or chronic eczematous dermatitis greater than 6.25 cm²
- Have SCORAD Index score of less than 50, indicating mild to moderate dermatitis.
- Able to read and write.
Who cannot join
- Allergic to fig extract
- Have dermatitis on face, genital area, palms, or soles.
- Used topical medications for itching or oral corticosteroids within 2 weeks
- Ppregnant or breastfeeding
- Participating in other clinical research studies
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to evaluate the efficacy and safety of a cream containing fig extract in volunteers with subacute and chronic eczematous dermatitis. The affected area of subacute and chronic eczematous dermatitis in each participant will be equally divided into two sections (left and right) using block randomization. One section (Area A) will receive the fig extract cream, while the other section (Area B) will receive a placebo cream as the control. All study assessments, including clinical assessments, skin parameter measurements, patient-reported outcomes, and adverse event assessments, will be performed at baseline and at 1, 2, and 3 weeks after treatment initiation.
Read the detailed description
The severity of subacute and chronic eczematous dermatitis will be assessed using the SCORAD Index and the Eczema Area and Severity Index (EASI). Clinical photographs will be taken to assess the affected area. Skin parameters, including erythema, melanin, hydration, and transepidermal water loss, will also be evaluated. Participants will additionally assess pruritus using the Visual Analogue Scale (VAS) and quality of life using the Dermatology Life Quality Index (DLQI).
- Being tested
- Fig extract cream, Placebo cream
- Keywords
- dermatitis
- Medical subject headings
- Dermatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fig extract creamOther
Fig extract cream
Placebo creamOther
Placebo cream
| Study group | Role | What they receive |
|---|---|---|
| Fig extract cream | Experimental | Apply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks. Receives: Other: Fig extract cream |
| Placebo cream | Placebo comparator | Apply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks. Receives: Other: Placebo cream |
What is being measured
The primary outcome is the main question the study is designed to answer.
The severity of subacute and chronic eczematous dermatitis
The severity of subacute and chronic eczematous dermatitis will be assessed using the SCORAD Index. The SCORAD Index ranges from 0 to 103, with higher scores indicating greater severity of eczematous dermatitis.
Measured: 3 weeks
Secondary outcomes (10)
Eczema Area and Severity Index (EASI)
The severity of subacute and chronic eczematous dermatitis will be assessed using the Eczema Area and Severity Index (EASI). The EASI Index ranges from 0 to 72, with higher scores indicating greater severity of eczematous dermatitis.
Measured: 3 weeks
Area of dermatitis
Clinical photographs will be taken to assess the affected area, with a reduction in the affected area indicating improvement after treatment.
Measured: 3 weeks
Erythema level
Erythema level will be assessed using a Mexameter. Higher erythema levels indicate greater severity of eczematous dermatitis.
Measured: 3 weeks
Melanin level
Melanin level will be assessed using a Mexameter.Higher melanin levels indicate greater severity of eczematous dermatitis.
Measured: 3 weeks
Skin hydration level
Skin hydration level will be assessed using a Corneometer. Lower hydration levels indicate greater severity of eczematous dermatitis.
Measured: 3 weeks
Transepidermal water loss level
Transepidermal water loss level will be assessed using a Tewameter. Higher transepidermal water loss levels indicate greater severity of eczematous dermatitis.
Measured: 3 weeks
Pruritus score
Pruritus score using the Visual Analogue Scale (VAS), ranging from 0 to 10, with higher scores indicating greater severity of itching.
Measured: 3 weeks
Quality of life score
Quality of life acore using the Dermatology Life Quality Index (DLQI), with higher scores indicating a greater impact of eczematous dermatitis on quality of life.
Measured: 3 weeks
Adverse events from using the products
Adverse events will be assessed by recording the presence or absence of itching, erythema, swelling, vesicles, abnormal breathing, and asthma symptoms.
Measured: 3 weeks
Satisfaction Score
Satisfaction Score will be assessed using a numerical rating scale from 0 to 10, where 0 indicates not satisfied at all and 10 indicates very satisfied.
Measured: 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 May 2027 (estimated)
- Study completion31 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Subacute and Chronic Eczematous Dermatitis VolunteersStudies of the same condition, open and under way.
- More trials run by Chulalongkorn UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chulalongkorn University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pornanong Aramwit, Pharm.D., Ph.D, Chulalongkorn University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07867249
- Sponsor's protocol ID
- Oh013-69
- Acronym
- Efficacy and s
- Status last verified
- Oct 2026
- First submitted
- 5 Oct 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Cream Containing Fig Extract in Subacute and Chronic Eczematous Dermatitis Volunteers
- ClinicalTrials.gov ID
- NCT07867249
- Acronym / sponsor ID
- Efficacy and s / Oh013-69
- Keywords
- dermatitis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Chulalongkorn UniversityUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 May 2027 (estimated)
- Study completion
- 31 May 2027 (estimated)
- First posted
- 9 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the efficacy and safety of a cream containing fig extract in volunteers with subacute and chronic eczematous dermatitis. The affected area of subacute and chronic eczematous dermatitis in each participant will be equally divided into two sections (left and right) using block randomization. One section (Area A) will receive the fig extract cream, while the other section (Area B) will receive a placebo cream as the control. All study assessments, including clinical assessments, skin parameter measurements, patient-reported outcomes, and adverse event assessments, will be performed at baseline and at 1, 2, and 3 weeks after treatment initiation.
Detailed description
The severity of subacute and chronic eczematous dermatitis will be assessed using the SCORAD Index and the Eczema Area and Severity Index (EASI). Clinical photographs will be taken to assess the affected area. Skin parameters, including erythema, melanin, hydration, and transepidermal water loss, will also be evaluated. Participants will additionally assess pruritus using the Visual Analogue Scale (VAS) and quality of life using the Dermatology Life Quality Index (DLQI).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fig extract cream | Experimental | Other: Fig extract creamApply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks. |
| Placebo cream | Placebo comparator | Other: Placebo creamApply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female participants aged 18 years or older.
- Have subacute or chronic eczematous dermatitis greater than 6.25 cm²
- Have SCORAD Index score of less than 50, indicating mild to moderate dermatitis.
- Able to read and write.
Key exclusion criteria (5 listed)
- Allergic to fig extract
- Have dermatitis on face, genital area, palms, or soles.
- Used topical medications for itching or oral corticosteroids within 2 weeks
- Ppregnant or breastfeeding
- Participating in other clinical research studies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fig extract creamFig extract cream | Other | Fig extract cream |
| Placebo creamPlacebo cream | Other | Placebo cream |
Primary outcome
The severity of subacute and chronic eczematous dermatitis
Time frame: 3 weeks
The severity of subacute and chronic eczematous dermatitis will be assessed using the SCORAD Index. The SCORAD Index ranges from 0 to 103, with higher scores indicating greater severity of eczematous dermatitis.
10 secondary outcomes
Eczema Area and Severity Index (EASI)
Time frame: 3 weeks
Area of dermatitis
Time frame: 3 weeks
Erythema level
Time frame: 3 weeks
Melanin level
Time frame: 3 weeks
Skin hydration level
Time frame: 3 weeks
Transepidermal water loss level
Time frame: 3 weeks
Pruritus score
Time frame: 3 weeks
Quality of life score
Time frame: 3 weeks
Adverse events from using the products
Time frame: 3 weeks
Satisfaction Score
Time frame: 3 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Fig extract cream in people with Subacute and Chronic Eczematous Dermatitis Volunteers, run by Chulalongkorn University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pornanong Aramwit, Professor (+66899217255, aramwit@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The severity of subacute and chronic eczematous dermatitis (time frame: 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.